ME1 and cancer: Studies have demonstrated that ME1 expression levels influence cancer susceptibility to oxidative phosphorylation (OXPHOS) inhibitors, with elevated ME1 expression diminishing the synthetic lethality between the pentose phosphate pathway (PPP) and OXPHOS.